ArticleRheumatology international2022
The clinical course of SARS-CoV-2 infection among children with rheumatic disease under biologic therapy: a retrospective and multicenter study.
Article in Rheumatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.
- Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.Journal of the Pediatric Infectious Diseases Society · 2024Pooled it
- Impaired Generation of High-Affinity Memory B Cells and Neutralizing Antibodies Against SARS-CoV-2 in Adolescents and Young Adults With Juvenile Idiopathic Arthritis Treated With Tumor Necrosis Factor Inhibitors.ACR open rheumatology · 2026Article
- Clinical characteristics and outcomes of COVID-19 in pediatric patients with rheumatic diseases.Pediatric research · 2025Observational
- The protective effect of biologic and targeted-synthetic therapies on developing multisystem inflammatory syndrome in children.Frontiers in pediatrics · 2025Article
- Serological response after COVID-19 infection compared to vaccination against COVID-19 in children with autoimmune rheumatic diseases.Pediatric rheumatology online journal · 2024Article
- Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.medRxiv : the preprint server for health sciences · 2024Article
- The impact of the COVID-19 pandemic on pediatric rheumatology practice: an international, cross-sectional survey study.Seminars in arthritis and rheumatism · 2023Article
- Article
- Coronavirus disease 2019 (COVID-19) in pediatric patients with autoimmune disorders.European journal of pediatrics · 2023Review
- Disease relapse rate in children with autoimmune rheumatic diseases after COVID-19 infection and vaccination.Pediatric rheumatology online journal · 2023Article
- COVID-19 in immunocompromised children and adolescents.Clinical and experimental pediatrics · 2023Article
- Childhood Multisystem Inflammatory Syndrome With Prominent Neurological Involvement.Pediatric neurology · 2022Article
- Implications of SARS-CoV-2 Infection in Systemic Juvenile Idiopathic Arthritis.International journal of molecular sciences · 2022Review
- Comparisons of Clinical Features and Outcomes of COVID-19 between Patients with Pediatric Onset Inflammatory Rheumatic Diseases and Healthy Children.Journal of clinical medicine · 2022Article
- Central nervous system manifestations of monogenic autoinflammatory disorders and the neurotropic features of SARS-CoV-2: Drawing the parallels.Frontiers in pediatrics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
30 authors at 14 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The effects of biological disease-modifying antirheumatic drugs (bDMARDs) in the clinical course of COVID-19 on children with underlying rheumatologic diseases have not been fully demonstrated. To evaluate the course of COVID-19 infection in patients with rheumatic disease receiving bDMARD treatment. This was a retrospective, multicenter study conducted in pediatric patients infected by SARS-CoV-2 and under bDMARDs therapy. The study population consisted of 113 patients (72 female/41 male). The mean age of the patients was 12.87 ± 4.69 years. The primary diagnosis of the cohort was as follows: 63 juvenile idiopathic arthritis, 35 systemic autoinflammatory diseases, 10 vasculitides, and five cases of connective tissue diseases. The mean duration of the primary disease was 4.62 ± 3.65 years. A total of 19 patients had additional comorbid diseases. Thirty-five patients were treated with canakinumab, 25 with adalimumab, 18 with etanercept, 10 with infliximab, nine with tocilizumab, six with rituximab, four with anakinra, three with tofacitinib, and one with abatacept. The median exposure time of the biological drug was 13.5 months. Seventy-one patients had symptomatic COVID-19, while 42 were asymptomatic. Twenty-four patients required hospitalization. Five patients presented with MIS-C. The hospitalized patients were younger and had a shorter duration of rheumatic disease compared to ambulatory patients, although the difference was not statistically significant. Steroid usage, presence of fever, and dyspnea were more common among the hospitalized patients. A worsening in the course of both COVID-19 and current disease was not noticed under bDMARDs, however, to end with a strong conclusion multicentric international studies are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.